Clinical trials: sponsored by Bristol-Myers Squibb
Myeloid Leukemia, Chronic
A Phase III Study of Dasatinib vs Imatinib in Patients With Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia
The purpose of this clinical research study is to compare the confirmed complete cytogenetic response of dasatinib with that of imatinib within 12 months after randomization in patients with newly diagnosed chronic-phase…
- Trial name
- DASISION (NCT00481247)
- Testing
- Dasatinib, Imatinib
- Where
- 109 sites in United States, Argentina and 25 more
- Volunteers
- 547 people
- Sponsor
- Bristol-Myers Squibb
Hepatitis C
Phase III Daclatasvir, Sofosbuvir, and Ribavirin in Cirrhotic Participants and Participants Post-liver Transplant
This trial was open to participants who had received a liver transplant or had cirrhosis due to chronic HCV. All subjects were treated with daclatasvir+sofosbuvir+ribavirin and were followed for 24 weeks post treatment.
- Trial name
- ALLY 1 (NCT02032875)
- Testing
- Daclatasvir, Sofosbuvir, Ribavirin
- Where
- 5 sites in United States
- Volunteers
- 116 people
- Sponsor
- Bristol-Myers Squibb
Malignant Melanoma
Expanded Access Program With Nivolumab in Combination With Ipilimumab in Patients With Tumors Unable to be Removed by Surgery or Metastatic Melanoma
The purpose of this study is to provide treatment with nivolumab in combination with ipilimumab to subjects who are anti-(CTLA)-4 and anti-PD-1 treatment-naive and have unresectable or metastatic melanoma.
- Trial name
- CheckMate218 (NCT02186249)
- Testing
- Nivolumab, Ipilimumab
- Where
- 66 sites in United States, Canada
- Sponsor
- Bristol-Myers Squibb
Hepatic Impairment
A Study to Evaluate the Pharmacokinetics of BMS-986141 in Participants With Hepatic Impairment Compared to Healthy Participants
An oral dose of BMS-986141 administered in Hepatic Impairment and Healthy Participants to evaluate pharmacokinetics in this patient population.
- Trial name
- NCT02985632
- Testing
- BMS-986141
- Where
- 3 sites in United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Solid Tumor
HuMax-IL8 (Interleukin8) in Patients With Advanced Malignant Solid Tumors
A phase Ib, dose escalation, multiple dose trial with HuMax-IL8 in patients with metastatic or unresectable, locally advanced malignant solid tumors.
- Trial name
- NCT02536469
- Testing
- HuMax-IL8
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Bristol-Myers Squibb
Hepatitis C
Safety and Efficacy Study of the Combination Daclatasvir (60 mg), Sofosbuvir (400 mg) and Ribavirin (Weight-based Dosing) for 12 or 16 Weeks in Subjects With Genotype 3 Chronic HCV Infection With or Without Prior Treatment Experience and Advanced Fibrosis or Compensated Cirrhosis
The purpose of the study is to determine if the combination of Daclatasvir, Sofosbuvir and Ribavirin for 12 or 16 weeks is safe and effective in the treatment of Genotype 3 Chronic Hepatitis C (HCV) in patients with advanced…
- Trial name
- NCT02319031
- Testing
- Daclatasvir, Sofosbuvir, Ribavirin
- Where
- 10 sites in Australia, France
- Volunteers
- 53 people
- Sponsor
- Bristol-Myers Squibb
Heart Failure
A First-in-Human Study of the Safety of Single Continuous Intravenous (IV) Infusions of CXL-1427 for up to 48 Hours in Healthy Volunteers
This study is designed to assess a safe dosage of the drug CXL-1427 (BMS-986231) in healthy volunteers.
- Trial name
- NCT02819271
- Testing
- CXL-1427 Ascending Dose, CXL-1427 Descending Dose
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Juvenile Rheumatoid Arthritis
BMS-188667 in Children and Adolescents With Juvenile Rheumatoid Arthritis
The primary purpose of the clinical research study is to assess the safety of treating children and juvenile subjects with BMS-188667 (Abatacept).
- Trial name
- NCT00095173
- Testing
- Abatacept
- Where
- 36 sites in United States, Austria and 9 more
- Volunteers
- 214 people
- Sponsor
- Bristol-Myers Squibb
Rheumatoid Arthritis
Survey on Long-Term Use of ORENCIA® Intravenous Infusion 250mg
The purpose of this study to collect information on the safety, especially serious infections and malignancies, and efficacy of the long-term use of ORENCIA Intravenous Infusion 250mg in patients with rheumatoid arthritis.
- Trial name
- NCT02600468
- Testing
- Orencia
- Volunteers
- 671 people
- Sponsor
- Bristol-Myers Squibb
Rheumatoid Arthritis
Use-Results Survey for ORENCIA® Subcutaneous Injection 125mg Syringe 1mL
The purpose of this study to collect information on the safety, especially localized injection site reactions, and efficacy of ORENCIA Subcutaneous Injection 125mg Syringe 1mL in patients with rheumatoid arthritis.
- Trial name
- NCT02600455
- Testing
- Orencia
- Where
- Japan
- Volunteers
- 505 people
- Sponsor
- Bristol-Myers Squibb
Rheumatoid Arthritis
An Exploratory Study of Changes in Synovial Immune Responses Following BMS-188667 Therapy in Subjects With Active Rheumatoid Arthritis on Background DMARDs Who Have Failed Anti-TNF Therapy
Study to assess changes in synovial tissue before and after treatment with Abatacept in subjects with RA who remained on their background disease modifying anti-arthritis medications but who have failed previous therapy with…
- Trial name
- NCT00162201
- Testing
- Abatacept
- Where
- United Kingdom
- Volunteers
- 16 people
- Sponsor
- Bristol-Myers Squibb
Thrombosis
A Study to Evaluate the Effect of Rifampin on the Single-dose Pharmacokinetics of BMS-986177 in Healthy Subjects
This study is to evaluate the effect of rifampin on the single-dose pharmacokinetics (PK) of BMS-986177 in healthy participants with parameters like Cmax, AUC(INF), AUC(0-T)
- Trial name
- NCT02959060
- Testing
- BMS-986177, Rifampin
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Renal Transplant
A Study of BMS-224818 (Belatacept) in Patients Who Have Undergone a Kidney Transplant and Are Currently on Stable Cyclosporine or Tacrolimus Regimen With or Without Corticosteroids
The purpose of this study is to learn if conversion to belatacept from cyclosporine or tacrolimus will preserve kidney function in people who have had a kidney transplant.
- Trial name
- NCT00402168
- Testing
- Belatacept, Cyclosporine A, Tacrolimus
- Where
- 44 sites in United States, Argentina and 10 more
- Volunteers
- 173 people
- Sponsor
- Bristol-Myers Squibb
Healthy Subjects
Safety Study of BMS-986165 in Healthy Subjects and to Treat Psoriasis
The purpose of this study is to establish if BMS-986165 is safe and effective at treating autoimmune diseases. BMS-986165 which has shown some promise in preclinical studies for inhibiting autoimmune conditions.
- Trial name
- NCT02534636
- Testing
- BMS-986165, Interferon alpha-2a recombinant, Famotidine
- Where
- Australia
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Arthritis
The Effect of BMS-986142 on the Pharmacokinetics of a Combined Oral Contraceptive (OC) Containing Ethinyl Estradiol (EE) and Norethindrone Acetate (NET) in Healthy Female Subjects
This is an open-label, 2-cycle, multiple-dose, single-sequence study in women of child-bearing potential. The primary objective is to assess the effect of BMS-986142 on the pharmacokinetics (PK) of Combined Oral Contraceptive…
- Trial name
- NCT02832180
- Testing
- OC containing EE and NET, BMS-986142
- Where
- 2 sites in United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Non-valvular Atrial Fibrillation
Real Evidence of Anticoagulation Treatment in Non-valvular Atrial Fibrillation in Germany, UK and France: REACT-AF2
The purpose of this study is to determine and compare the persistence rate of newly prescribed apixaban, rivaroxaban, dabigatran and VKAs in patients with NVAF.
- Trial name
- REACT-AF2 (NCT02488421)
- Volunteers
- 38,122 people
- Sponsor
- Bristol-Myers Squibb
Ischemic Stroke
A Study to Evaluate the Effect of Diltiazem on the Pharmacokinetics (PK) of BMS-986141 in Healthy Subjects
This study is to evaluate the effect of dilitazem on the single-dose PK of BMS-986141 with parameters like Cmax, AUC(INF), and AUC(0-T).
- Trial name
- NCT02922452
- Testing
- BMS-986141, Dilitazem
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Rheumatoid Arthritis
Safety Study of Abatacept to Treat Rheumatoid Arthritis (A)
The purpose of this study is to compare the incidence rates of infection among patients with rheumatoid arthritis who are treated with abatacept and those who are treated with other anti-rheumatic medications
- Trial name
- NCT01088321
- Volunteers
- 81,332 people
- Sponsor
- Bristol-Myers Squibb
Chronic Phase Chronic Myeloid Leukemia
Phase IV, Open-label, Multicenter Study of Dasatinib in Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients With Chronic, Low-grade Non-Hematologic Toxicity to Imatinib
This study proposes to evaluate the number of chronic, Grade 1 or 2, non-hematologic Adverse Events (AEs) that reduce in grade or resolve at 3 months after switching therapy from imatinib to dasatinib.
- Trial name
- NCT01660906
- Testing
- Dasatinib
- Where
- 22 sites in United States, France and 3 more
- Volunteers
- 39 people
- Sponsor
- Bristol-Myers Squibb
Venous Thromboembolism
Effect of Clarithromycin on the Pharmacokinetics of Apixaban in Healthy Participants
This study is to evaluate the effects of multiple-dose clarithromycin on the single-dose pharmacokinetics (PK) of apixaban with parameters like Cmax, AUC(INF), and AUC(0-T).
- Trial name
- NCT02912234
- Testing
- Apixaban, Clarithromycin
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.